IRIS
TAGLIAMENTO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.035
AS - Asia 393
NA - Nord America 74
SA - Sud America 68
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.573
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.021
SG - Singapore 142
CN - Cina 107
VN - Vietnam 107
US - Stati Uniti d'America 63
BR - Brasile 48
HK - Hong Kong 13
AR - Argentina 11
MX - Messico 8
BD - Bangladesh 6
ID - Indonesia 6
RU - Federazione Russa 5
UZ - Uzbekistan 3
EC - Ecuador 2
UY - Uruguay 2
VE - Venezuela 2
ZA - Sudafrica 2
AL - Albania 1
CA - Canada 1
CL - Cile 1
DE - Germania 1
DO - Repubblica Dominicana 1
ES - Italia 1
GB - Regno Unito 1
GE - Georgia 1
GY - Guiana 1
IL - Israele 1
IN - India 1
IQ - Iraq 1
KG - Kirghizistan 1
KR - Corea 1
MK - Macedonia 1
MM - Myanmar 1
PA - Panama 1
PH - Filippine 1
PL - Polonia 1
PY - Paraguay 1
RS - Serbia 1
SE - Svezia 1
TH - Thailandia 1
UA - Ucraina 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.573
Salva come PNG Salva come JPEG
Città #
Genoa 2.951
Genova 927
Vado Ligure 630
Rapallo 474
Ho Chi Minh City 39
Ashburn 36
Beijing 33
Singapore 33
Hanoi 21
Bordighera 14
Hong Kong 13
Tianjin 10
Milan 7
São Paulo 6
Mexico City 5
Da Nang 4
Haiphong 4
Hải Dương 4
Phủ Lý 4
Thái Bình 4
Chicago 3
Hefei 3
Rome 3
Thái Nguyên 3
Beinasco 2
Biên Hòa 2
Bình Dương 2
Dhaka 2
Fortaleza 2
Lancaster 2
Orem 2
Phoenix 2
Salt Lake City 2
Tashkent 2
Verona 2
Villasanta 2
Acolman 1
Ananindeua 1
Arapiraca 1
Asunción 1
Atlanta 1
Açailândia 1
Baltimore 1
Barrinha 1
Belgrade 1
Bengaluru 1
Birigui 1
Bishkek 1
Boca Toma 1
Bắc Giang 1
Bắc Ninh 1
Campinas 1
Canela 1
Canindé de São Francisco 1
Cape Town 1
Caracas 1
Carangola 1
Cayambe 1
Chapecó 1
Chengdu 1
Ciudad Guayana 1
Cuiabá 1
Curitiba 1
Córdoba 1
Dalseong-gun 1
Diadema 1
Donetsk 1
Duhok 1
Duque de Caxias 1
Embu das Artes 1
General Pico 1
Georgetown 1
Guangzhou 1
Gustavo Adolfo Madero 1
Ha Long 1
Houston 1
Huauchinango 1
Hưng Yên 1
Ipaba 1
Isidro Casanova 1
Jakarta 1
Jersey City 1
Johannesburg 1
Juiz de Fora 1
Kanchanaburi 1
Kista 1
La Plata 1
Las Flores 1
Linhares 1
Llambí Campbell 1
Los Angeles 1
Makhachkala 1
Maldonado 1
Manado 1
Manchester 1
Manila 1
Milagres 1
Milwaukee 1
Monte Grande 1
Montes Claros 1
Totale 5.319
Salva come PNG Salva come JPEG
Nome #
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 217
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 197
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 179
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 156
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 143
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 135
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 125
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 125
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 125
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 124
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 120
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 116
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 115
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 111
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 111
Radiomic detection of EGFR mutations in NSCLC 109
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 107
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test 107
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 105
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 103
Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women 103
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 101
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 98
Update on the management of breast cancer during pregnancy 97
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 96
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 93
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 92
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 91
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 90
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 89
Novel emerging molecular targets in non-small cell lung cancer 86
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 83
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 82
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 81
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 80
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 79
Call for ensuring cancer care continuity during COVID-19 pandemic 79
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab 72
Performance of the oncomineTM Lung cfDNA assay for liquid biopsy by NGS of NSCLC patients in routine laboratory practice 71
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 70
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 69
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study 67
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 66
Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient 64
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 63
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 61
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 59
null 57
Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity 56
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis” 55
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 51
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies 50
Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer 47
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 44
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates 41
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 41
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 40
The evolving scenario of cancer care provision across the COVID-19 pandemic in Europe 38
VISTA: A Promising Target for Cancer Immunotherapy? 38
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 36
Expected medium- And long-term impact of the COVID-19 outbreak in oncology 35
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 34
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 33
Oncological care organisation during COVID-19 outbreak 32
Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction 31
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer 28
Heterogeneity of treatment effects in malignant pleural mesothelioma 24
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 24
Does perioperative immunotherapy reduce the risk of second primary cancers? 24
New emerging targets in cancer immunotherapy: The role of VISTA 23
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors 23
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey 17
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma 17
The use of immunotherapy in older patients with advanced non-small cell lung cancer 15
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses 15
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives 12
Data from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates 7
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 7
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer 6
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study 6
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives 4
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer 4
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer 4
Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer 4
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases 2
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease 1
Time to rethink platinum choices in the era of immunotherapy in lung cancer 1
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer 1
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer 1
Tackling Non–Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes 1
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients 1
Totale 5.843
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.032
article - articoli 24.849
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 25
Totale 49.906
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021180 0 0 0 0 0 18 12 38 31 47 12 22
2021/2022394 38 13 9 29 21 25 16 79 32 52 21 59
2022/2023567 43 53 5 48 93 81 7 46 97 12 75 7
2023/2024475 11 33 11 55 27 85 36 36 17 42 39 83
2024/20251.854 78 102 43 115 220 199 202 342 104 91 194 164
2025/20261.928 350 154 580 397 383 64 0 0 0 0 0 0
Totale 5.843